Certain Selective Thyroid Hormone Receptor-Beta Agonists, Processes for Manufacturing or Relating to Same, and Products Containing Same; Notice of a Commission Determination Not To Review an Initial Determination Granting a Motion To Intervene, 66896-66897 [2023-21140]

Download as PDF ddrumheller on DSK120RN23PROD with NOTICES1 66896 Federal Register / Vol. 88, No. 187 / Thursday, September 28, 2023 / Notices information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205–1810. SUPPLEMENTARY INFORMATION: On October 21, 2022, the Commission instituted this investigation based on a complaint filed by Maxell, Ltd. (‘‘Maxell’’) of Kyoto, Japan. 87 FR 64110 (Oct. 21, 2022). The complaint alleged violations of section 337 based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain smart televisions by reason of infringement of one or more of claim 4 of U.S. Patent No. 8,549,109; claims 2, 4, 5, 7, and 8 of U.S. Patent No. 8,170,394; claim 1 of U.S. Patent No. 10,958,971; and claims 1 and 21 of U.S. Patent No. 11,017,815. Id. The Commission’s notice of investigation named VIZIO, Inc. (‘‘VIZIO’’) of Irvine, California as the sole respondent. The Office of Unfair Import Investigations was not named as a party in this investigation. Id. On August 25, 2023, Maxell and VIZIO jointly moved to terminate the investigation in its entirety based upon reaching a settlement agreement. On August 30, 2023, the ALJ issued the subject ID granting the motion. The ID observed that Commission Rule 210.21(a)(2) provides that ‘‘[a]ny party may move at any time to terminate an investigation in whole or in part as to any or all respondents on the basis of settlement, a licensing or other agreement . . . .’’ ID at 1 (citing 19 CFR 210.21(a)(2)). The ID found that in compliance with 19 CFR 210.21(b)(1), the parties certify that ‘‘there are no other agreements, written or oral, express or implied, between the parties concerning the subject matter of the investigation.’’ Id. The parties also submitted confidential and public versions of the settlement agreement. Id. The ID further found that ‘‘termination of this investigation by settlement will not adversely affect the public interest.’’ Id. (citing 19 CFR 210.50(b)(2)). No one petitioned for review of the subject ID. The Commission has determined not to review the subject ID. The investigation is hereby terminated in its entirety. The Commission vote for this determination took place on September 22, 2023. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as VerDate Sep<11>2014 18:09 Sep 27, 2023 Jkt 259001 amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). INTERNATIONAL TRADE COMMISSION By order of the Commission. Issued: September 25, 2023. Lisa Barton, Secretary to the Commission. Certain Selective Thyroid Hormone Receptor-Beta Agonists, Processes for Manufacturing or Relating to Same, and Products Containing Same; Notice of a Commission Determination Not To Review an Initial Determination Granting a Motion To Intervene [FR Doc. 2023–21260 Filed 9–27–23; 8:45 am] BILLING CODE 7020–02–P [Investigation No. 337–TA–1352] International Trade Commission. ACTION: Notice. AGENCY: INTERNATIONAL TRADE COMMISSION Sunshine Act Meetings United States International Trade Commission. AGENCY HOLDING THE MEETING: TIME AND DATE: October 12, 2023 at 9:30 a.m. Room 101, 500 E Street SW, Washington, DC 20436, Telephone: (202) 205–2000. PLACE: STATUS: Open to the public. MATTERS TO BE CONSIDERED: 1. Agendas for future meetings: none. 2. Minutes. 3. Ratification List. 4. Commission vote on Inv. No. 731– TA–891 (Fourth Review) (Foundry Coke from China). The Commission currently is scheduled to complete and file its determinations and views of the Commission on October 20, 2023. 5. Outstanding action jackets: none. CONTACT PERSON FOR MORE INFORMATION: Sharon Bellamy, Supervisory Hearings and Information Officer, 202–205–2000. The Commission is holding the meeting under the Government in the Sunshine Act, 5 U.S.C. 552(b). In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting. By order of the Commission. Issued: September 26, 2023. Sharon Bellamy, Supervisory Hearings and Information Officer. [FR Doc. 2023–21534 Filed 9–26–23; 4:15 pm] BILLING CODE 7020–02–P PO 00000 Frm 00101 Fmt 4703 Notice is hereby given that the U.S. International Trade Commission (the ‘‘Commission’’) has determined not to review an initial determination (‘‘ID’’) (Order No. 37) granting a motion to intervene in the above-captioned investigation. FOR FURTHER INFORMATION CONTACT: Carl P. Bretscher, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2382. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket system (‘‘EDIS’’) at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on February 9, 2023, based on a complaint, as supplemented, filed by Viking Therapeutics, Inc. of San Diego, California (‘‘Viking’’). 88 FR 8455–56 (Feb. 9, 2023). The complaint alleges a violation of section 337 the Tariff Act, as amended, 19 U.S.C. 1337, by way of the importation, sale for importation, or sale in the United States after importation of certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure a domestic industry or prevent the establishment of a domestic industry. Id. The named respondents include Ascletis Pharma Inc. of Hangzhou, Zhejiang Province, China; Ascletis Pharmaceuticals Co. of Shaoxing, Zhejiang Province, China; Ascletis SUMMARY: [USITC SE–23–048] Sfmt 4703 E:\FR\FM\28SEN1.SGM 28SEN1 ddrumheller on DSK120RN23PROD with NOTICES1 Federal Register / Vol. 88, No. 187 / Thursday, September 28, 2023 / Notices Bioscience Co. of Hangzhou, Zhejiang Province, China; Gannex Pharma Co. of Shanghai, China; and Jinzi Jason Wu of Seattle, Washington (all collectively, ‘‘the Ascletis Respondents’’). Id. The Office of Unfair Import Investigation is also participating in the investigation. Id. On June 30, 2023, Viking filed an Omnibus Motion for Monetary and NonMonetary Sanctions Against Respondents and their Counsel, alleging failure to cooperate during discovery, failure to cooperate during forensic examinations, and violations of the terms of certain orders. On August 10, 2023, Foster, Murphy, Altman & Nickel, PC (‘‘Foster Murphy’’) moved to intervene in this investigation for the limited purpose of defending Foster Murphy and its attorneys’ interest in response to complainant Viking’s omnibus motion for sanctions. The motion was unopposed. On August 28, 2023, the presiding administrative law judge (‘‘ALJ’’) issued the subject ID (Order No. 37) pursuant to Commission Rule 210.19 (19 CFR 210.19) granting Foster Murphy’s motion to intervene. Order No. 37 (Aug. 28, 2023). The ALJ states that the sanctions motion seeks joint and several liability between the Ascletis Respondents and Foster Murphy for discovery abuse. Id. at 4–5. The ALJ finds that Viking’s sanctions motion makes specific allegations that implicate Foster Murphy and its attorneys. Id. at 5. The ALJ finds that, in view of these separate interests, the limited purpose of the intervention, and the lack of opposition, Foster Murphy’s motion to intervene is granted. Id. at 6. No party filed a petition for review. The Commission has determined not to review the subject ID. The Commission vote for this determination took place on September 22, 2023. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: September 22, 2023. Katherine Hiner, Supervisory Attorney. [FR Doc. 2023–21140 Filed 9–27–23; 8:45 am] BILLING CODE 7020–02–P VerDate Sep<11>2014 18:09 Sep 27, 2023 Jkt 259001 DEPARTMENT OF JUSTICE Notice of Lodging of Proposed Consent Decree Under the Clean Water Act On September 19, 2023, the Department of Justice lodged a proposed Consent Decree (the ‘‘Consent Decree’’) with the District Court of the Southern District of New York in a lawsuit entitled United States of America, et al. v. City of Mount Vernon., Civil Action No. 18–5845. In this action, the United States and State of New York seek injunctive relief compelling the City of Mount Vernon to comply with the Clean Water Act in its operation of a municipal separate storm sewer system. The lawsuit also seeks civil penalties for past violations. The proposed Consent Decree resolves the United States’ and States’ civil claims. It imposes injunctive relief requiring Mount Vernon to take steps necessary to bring its municipal separate storm sewer system into compliance. It also requires Mount Vernon to pay a $100,000 civil penalty to the United States and imposes (but suspends payment of) a $100,000 civil penalty owed to the State of New York. The publication of this notice opens the public comment on the proposed settlement. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States of America, et al. v. City of Mount Vernon, DJ # 90–5–1–1–11743. All comments must be submitted no later than 30 days after the publication date of this notice. Comments may be submitted either by email or by mail: To submit comments: Send them to: By email ....... pubcomment-ees.enrd@ usdoj.gov. Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. By mail ......... During the public comment period, the settlement may be examined and downloaded at this Justice Department website: https://www.usdoj.gov/enrd/ Consent_Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. The Consent Decree has voluminous exhibits, so please specify in your request whether you wish the exhibits to be included. Please mail your request and payment to: Consent Decree Library, U.S. DOJ— ENRD, P.O. Box 7611, Washington, DC 20044–7611. PO 00000 Frm 00102 Fmt 4703 Sfmt 4703 66897 Please enclose a check or money order for $11.75 (for the Consent Decree without exhibits) or $189.00 (for the Consent Decree with exhibits) (25 cents per page reproduction cost) payable to the United States Treasury. Henry S. Friedman, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2023–21124 Filed 9–27–23; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE [OMB Number 1123–0NEW] Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Authorization for Release of Information Office of the Pardon Attorney, Department of Justice. ACTION: 60-Day notice. AGENCY: The Office of the Pardon Attorney, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until November 27, 2023. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Kira Gillespie, Deputy Pardon Attorney, Office of the Pardon Attorney, 950 Pennsylvania Avenue NW, Main Justice—RFK Building, Washington, DC 20530; kira.gillespie@usdoj.gov; (202) 616–6073. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Office of the Pardon Attorney, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, SUMMARY: E:\FR\FM\28SEN1.SGM 28SEN1

Agencies

[Federal Register Volume 88, Number 187 (Thursday, September 28, 2023)]
[Notices]
[Pages 66896-66897]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21140]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1352]


Certain Selective Thyroid Hormone Receptor-Beta Agonists, 
Processes for Manufacturing or Relating to Same, and Products 
Containing Same; Notice of a Commission Determination Not To Review an 
Initial Determination Granting a Motion To Intervene

AGENCY: International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission (the ``Commission'') has determined not to review an initial 
determination (``ID'') (Order No. 37) granting a motion to intervene in 
the above-captioned investigation.

FOR FURTHER INFORMATION CONTACT: Carl P. Bretscher, Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street SW, 
Washington, DC 20436, telephone (202) 205-2382. Copies of non-
confidential documents filed in connection with this investigation may 
be viewed on the Commission's electronic docket system (``EDIS'') at 
https://edis.usitc.gov. For help accessing EDIS, please email 
[email protected]. General information concerning the Commission may 
also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on 
this matter can be obtained by contacting the Commission's TDD 
terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on February 9, 2023, based on a complaint, as supplemented, filed by 
Viking Therapeutics, Inc. of San Diego, California (``Viking''). 88 FR 
8455-56 (Feb. 9, 2023). The complaint alleges a violation of section 
337 the Tariff Act, as amended, 19 U.S.C. 1337, by way of the 
importation, sale for importation, or sale in the United States after 
importation of certain selective thyroid hormone receptor-beta 
agonists, processes for manufacturing or relating to same, and products 
containing same by reason of misappropriation of trade secrets, the 
threat or effect of which is to destroy or substantially injure a 
domestic industry or prevent the establishment of a domestic industry. 
Id. The named respondents include Ascletis Pharma Inc. of Hangzhou, 
Zhejiang Province, China; Ascletis Pharmaceuticals Co. of Shaoxing, 
Zhejiang Province, China; Ascletis

[[Page 66897]]

Bioscience Co. of Hangzhou, Zhejiang Province, China; Gannex Pharma Co. 
of Shanghai, China; and Jinzi Jason Wu of Seattle, Washington (all 
collectively, ``the Ascletis Respondents''). Id. The Office of Unfair 
Import Investigation is also participating in the investigation. Id.
    On June 30, 2023, Viking filed an Omnibus Motion for Monetary and 
Non-Monetary Sanctions Against Respondents and their Counsel, alleging 
failure to cooperate during discovery, failure to cooperate during 
forensic examinations, and violations of the terms of certain orders.
    On August 10, 2023, Foster, Murphy, Altman & Nickel, PC (``Foster 
Murphy'') moved to intervene in this investigation for the limited 
purpose of defending Foster Murphy and its attorneys' interest in 
response to complainant Viking's omnibus motion for sanctions. The 
motion was unopposed.
    On August 28, 2023, the presiding administrative law judge 
(``ALJ'') issued the subject ID (Order No. 37) pursuant to Commission 
Rule 210.19 (19 CFR 210.19) granting Foster Murphy's motion to 
intervene. Order No. 37 (Aug. 28, 2023). The ALJ states that the 
sanctions motion seeks joint and several liability between the Ascletis 
Respondents and Foster Murphy for discovery abuse. Id. at 4-5. The ALJ 
finds that Viking's sanctions motion makes specific allegations that 
implicate Foster Murphy and its attorneys. Id. at 5. The ALJ finds 
that, in view of these separate interests, the limited purpose of the 
intervention, and the lack of opposition, Foster Murphy's motion to 
intervene is granted. Id. at 6.
    No party filed a petition for review.
    The Commission has determined not to review the subject ID.
    The Commission vote for this determination took place on September 
22, 2023.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: September 22, 2023.
Katherine Hiner,
Supervisory Attorney.
[FR Doc. 2023-21140 Filed 9-27-23; 8:45 am]
BILLING CODE 7020-02-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.